Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the ...

For years, MASH was where drug development dreams went to die.  | After Rezdiffra’s approval and Wegovy’s label expansion, ...

PHOENIX — The oral medication resmetirom significantly improved liver stiffness and reduced portal hypertension in metabolic ...

Madrigal Pharmaceuticals sees rapid Rezdiffra sales growth with EU approval and long-term GLP-1 strategy. Learn why MDGL ...

Bill Sibold, Madrigal Pharma CEO, joins 'Fast Money' to talk how Rezdiffra stacks up to competitors in the MASH treatment space, sales growth for the drug over the last year, and more.

With the business potentially at an important milestone, we thought we'd take a closer look at Madrigal Pharmaceuticals, Inc.'s (NASDAQ:MDGL) future prospects. Madrigal Pharmaceuticals, Inc., a ...

The announcement comes three months after all the region's Chando's Tacos locations abruptly shut down. In the months since, ...